-
Mashup Score: 2
TIVO-3 randomized phase 3 trial of tivozanib, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, CONTACT-03 phase 3 trial, TiNivo-2 trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
TIVO-3 randomized phase 3 trial of tivozanib, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, CONTACT-03 phase 3 trial, TiNivo-2 trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Should we be surprised that in the TiNivo-2 trial, tivozanib + nivolumab is negative when compared to tivozanib monotherapy, after progression on a prior immune checkpoint inhibitor? #COE #Blog from Evan Yu, MD @fredhutch. #ReadNow on UroToday > https://t.co/iSVOLp3wLP https://t.co/uo4UHQSir1
-
-
Mashup Score: 0
TIVO-3 randomized phase 3 trial of tivozanib, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, CONTACT-03 phase 3 trial, TiNivo-2 trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Should we be surprised that in the TiNivo-2 trial, tivozanib + nivolumab is negative when compared to tivozanib monotherapy, after progression on a prior immune checkpoint inhibitor? #COE #Blog from Evan Yu, MD @fredhutch. #ReadNow on UroToday > https://t.co/iSVOLp3wLP https://t.co/uo4UHQSir1
-
Should we be surprised that in the TiNivo-2 trial, tivozanib + nivolumab is negative when compared to tivozanib monotherapy, after progression on a prior immune checkpoint inhibitor? #COE #Blog from Evan Yu, MD @fredhutch. #ReadNow on UroToday > https://t.co/iSVOLp3wLP https://t.co/uo4UHQSir1